The US Food and Drug Administration has announced a nationwide Class II recall of certain levothyroxine sodium tablets after they were found to be subpotent, meaning they may contain less active ingredient than intended. The medicine is widely used to treat an underactive thyroid and other thyroid conditions, so affected patients may receive less effective treatment and should seek advice before changing their medication.

Major Pharmaceuticals issued the recall on 13 July, with the FDA classifying it on 17 July. It covers specified lots in doses ranging from 25 to 150 micrograms, distributed nationwide by Major Pharmaceuticals and, for some products, Cardinal Health; the FDA did not state how many tablets were affected. A Class II recall indicates that adverse effects may be temporary or medically reversible, while serious consequences are considered unlikely.